Axogen Inc vs Phillips 66 — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Phillips 66 trades at $225.5 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 34.3× Axogen Inc's market cap, and Phillips 66 pays a 2.26% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | PSX | |
|---|---|---|
Market Cap | $2.61B | $89.52B |
Sector | Technology | Energy |
52-Week High | $48.48 | $224.36 |
52-Week Low | $14.16 | $120.04 |
Enterprise Value | $2.52B | $105.99B |
Dividend Yield | — | 2.26% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
Phillips 66 (PSX) trades at $225.48, up 4.62% today, with a bullish technical signal supported by moving averages and strong earnings beats. Recent Q2 2026 EPS of $9.41 exceeded expectations, driven by robust refining margins. The company announced a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream operations. Valuation metrics appear attractive with a P/E of 12.81 and P/S of 0.6, while profitability remains solid with a 24.02% ROE.
Outlook is positive due to sustained refining tightness and debt reduction, but risks include volatile crude prices and regulatory pressures. Analysts are bullish with a $221.92 consensus target, though the stock faces near-term resistance at $227. Revenue is projected to rebound to $152.2B in 2026, supporting a hold or buy stance for long-term investors.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →